ODN 698
Latest Information Update: 30 Aug 2002
At a glance
- Originator Novartis
- Class Antineoplastics; Antisense oligonucleotides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 22 Jun 1999 Phase-II clinical trials for Solid tumours in USA (IV)